GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Forward PE Ratio

Moderna (LTS:0A45) Forward PE Ratio : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Moderna Forward PE Ratio?

Moderna's Forward PE Ratio for today is 0.00.

Moderna's PE Ratio without NRI for today is 0.00.

Moderna's PE Ratio for today is 0.00.


Moderna Forward PE Ratio Historical Data

The historical data trend for Moderna's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Forward PE Ratio Chart

Moderna Annual Data
Trend 2020-12 2021-12 2022-12 2023-02
Forward PE Ratio
40.49 9.84 27.55 23.53

Moderna Quarterly Data
2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12
Forward PE Ratio 45.87 40.49 7.79 9.33 14.56 9.84 6.00 5.58 21.37 27.55

Competitive Comparison of Moderna's Forward PE Ratio

For the Biotechnology subindustry, Moderna's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Moderna's Forward PE Ratio falls into.



Moderna Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Moderna  (LTS:0A45) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Moderna Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Moderna's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (LTS:0A45) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines